Samrat Pharmachem Hits New 52-Week Low at Rs. 285.1

Samrat Pharmachem, a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week low of Rs. 285.1 today, October 15, 2025. This decline marks a notable underperformance, as the stock has fallen by 4.67% over the past three days, continuing a downward trend that has seen it underperform its sector by 2.29% today.
The stock's performance has been consistently below key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a challenging market position. Over the past year, Samrat Pharmachem has experienced a substantial decline of 47.18%, contrasting sharply with the Sensex's modest gain of 0.96% during the same period.

In terms of financial health, the company has reported a flat performance in its latest quarterly results, with a PAT of Rs. 2.15 crore reflecting a decrease of 43.57%. The stock's return on capital employed (ROCE) stands at 3.9%, and it is currently trading at a premium compared to its peers' historical valuations. Despite these challenges, foreign institutional investors have increased their holdings to 3.24% this quarter.